SHANK2

Across TCGA pan-cancer cohorts, SHANK2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SHANK2 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SHANK2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SHANK2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where SHANK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.982	0.524	.009	22	view →
GBM	DFS	Median	All	0.826	0.667	.006	8	view →
PDAC	OS	Tertile	All	0.877	0.699	.020	2	view →
LSCC	OS	Quartile	All	0.751	0.957	.032	2	view →
HNSC	DFS	Median	IV	0.335	1.000	.036	2	view →
LUAD	DFS	Median	All	0.525	0.729	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SHANK2–CCRCC (DFS)

Open the CCRCC breakdown →